To explore the in vivo anti-tumor activity of TIGIT blockade antibodies and evaluate the relative contribution of Fc functions in anti-tumor efficacy, we performed mouse efficacy studies using CT26.WT tumor model in BALB/c mice (for surrogate TIGIT mAb study) or human TIGIT knock-in mice (for humanized TIGIT mAb study). This evidence concerns the gene DDX53 and neoplasm.